VKORC1 polymorphisms in Brazilians: Comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications

Pharmacogenomics

Volumn 11, Issue 9, 2010, Pages 1257-1267

  Suarez Kurtz, Guilherme ^a   Amorim, Antnio ^b   Damasceno, Albertino ^c   Hutz, Mara H ^d   Moraes, Manuel Odorico De ^e   Ojopi, Élida B ^f   Pena, Sérgio D J ^g,h   Perini, Jamila A ^a   Prata, Maria Joo ^b   Ribeiro Dos Santos, Andrea ⁱ   Romano Silva, Marco A ^g   Teixeira, Daniel ^b   Struchiner, Claudio José ^j  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b UNIVERSITY OF PORTO   (Portugal)

^c EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h Nucleo de Genet Medica de MG   (Brazil)

ⁱ FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^j INSTITUTO OSWALDO CRUZ   (Brazil)

more..

Author keywords

Africans; ancestry; Brazilians; human diversity; Portuguese; VKORC1 polymorphisms; warfarin dosing algorithms

Indexed keywords

ENZYME; PROTEIN VKORC1; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AFRICAN AMERICAN; ANGOLA; ARTICLE; ARTIFICIAL NEURAL NETWORK; BRAZIL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE CALCULATION; DRUG SENSITIVITY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE LINKAGE DISEQUILIBRIUM; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC ORIGIN; HAPLOTYPE; HUMAN; MOZAMBIQUE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POPULATION GENETIC STRUCTURE; PORTUGAL; RACE DIFFERENCE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGOLA; ANTICOAGULANTS; BRAZIL; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HAPLOTYPES; HUMANS; MIXED FUNCTION OXYGENASES; MOZAMBIQUE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PORTUGAL; WARFARIN;

EID: 77957125324     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.89     Document Type: Article

References (27)

1. Bastos-Rodrigues L, Pimenta JR, Pena SDJ: The genetic structure of human populations studied through short insertion-deletion polymorphisms. Ann. Hum. Genet. 70, 658-665 (2006).
2. Suarez-Kurtz G, Vargens, DD, Struchiner CJ et al.: Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet. Genom. 17, 765-772 (2007).
3. Pena SDJ, Bastos Rodrigues L, Pimenta JL, Bydlowski SP: DNA tests probe the genomic ancestry of Brazilians. Braz. J. Med. Biol. Res. 42, 870-876 (2009).
4. Suarez-Kurtz G: Pharmacogenetics in admixed populations. Trends Pharmacol. Sci. 26, 196-201 (2005).
5. Suarez-Kurtz G, Pena SDJ: Pharmacogenetic Studies in the Brazilian Population. In Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.) Landes Biosciences, TX, USA, 75-98 (2007).
6. Suarez-Kurtz G, Pena SDJ: Pharmacogenomics in the Americas: impact of genetic admixture. Curr. Drug Targets 7, 1649-1658 (2006).
7. Suarez-Kurtz G: Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network-REFARGEN. Pharmacogenomics J. 4, 347-348 (2004).
8. Li T, Chang CY, Jin DY et al.: Identifcation of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
9. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor defciency type 2. Nature 427, 537-541 (2004).
10. Jonas DE, McLeod HL: Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci. 30, 375-386 (2009).
11. Perini JA, Struchiner CJ, Silva-Assunção E et al.: Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84, 722-728 (2008).
12. Suarez-Kurtz G, Perini JA,Silva-Assunção E, Struchiner CJ: Relative contribution of VKORC1, CYP2C9 and INR response to warfarin stable dose Blood 113, 4125-4126 (2009).
13. International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
14. Limdi NA, Wadelius M, Cavallari L et al.: Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood 115, 3827-3834 (2010).
15. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 155, 945-959 (2000).
16. Excoffer L, Laval G, Schneider S: Arlequin (version 3.0): an integrated software package for population genetics data ana lysis. Evol. Bioinform. Online 1, 47-50 (2005).
17. Venables WN, Ripley BD: Modern Applied Statistics with S. (4th Edition). Springer, NY, USA (2002).
18. Fox J: Effect displays in R for generalised linear models. J. Stat. Softw. 8, 1-27 (2003).
19. R Core Development Team: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2009).
20. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L et al.: Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8, 1299-1306 (2007).
21. Estrela RCE, Ribeiro FS, Carvalho RS et al.: The distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9, 267-276 (2008).
22. Vargens DD, Almendra L, Struchiner CJ, Suarez-Kurtz G: Distribution of the GNB3 825C T polymorphism among Brazilians: impact of population structure. Eur. J. Clin. Pharmacol. 3, 253-256 (2008).
23. Suarez-Kurtz G: The implications of population admixture in race-based therapy Clin. Pharmacol. Ther. 3, 399-400 (2008).
24. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
25. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007).
26. Limdi NA, McGwin G, Goldstein JA et al.: Infuence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321 (2008).
27. Zembrzuski VM, Callegari-Jacques SM, Hutz MH: Application of an African ancestry index as a genomic control approach in a Brazilian population. Ann. Hum. Genet. 70, 822-828 (2006).